BPC-157

BPC-157 emerged from research into biologically active compounds associated with gastric juice. In 1993, Predrag Sikiric and colleagues described the gastric peptide research program and its proposed connection to stress-related organ protection in experimental models.¹ Early investigations centered on the stomach and gastrointestinal tract. Over time, the research expanded into other preclinical injury models, including muscle, tendon and nerve tissue. A 2003 study, for example, examined healing in transected rat Achilles tendons and the growth of tendon-derived cells in culture.² This progression moved BPC-157 from a narrowly gastrointestinal research subject into a broader experimental model for studying tissue responses to injury. Later reviews brought together findings involving vascular signaling, connective tissue and organ-protection models.³ Despite more than three decades of investigation, the evidence base remains dominated by animal and laboratory studies. Controlled human research is limited, and preclinical findings should not be interpreted as proof of clinical benefit.

BPC-157 does not have one confirmed receptor that accounts for its reported activity. Instead, preclinical research suggests that it influences several connected pathways involved in vascular signaling, cell movement and tissue responses to injury.³ One proposed mechanism involves VEGFR2. In experimental models, BPC-157 was associated with VEGFR2 activation and downstream Akt–eNOS signaling, a pathway involved in endothelial-cell activity and new blood-vessel formation.⁴ Research has also linked the peptide to the nitric-oxide system, including modulation of vascular responses under different experimental conditions.⁵ Another area of study involves focal adhesion kinase (FAK) and paxillin. These proteins help regulate cell attachment and migration; tendon-derived cell experiments associated BPC-157 with changes in these repair-related processes.² Additional models have examined inflammatory signaling, major-vessel occlusion and ischemia–reperfusion injury.⁶ Together, these findings support a multi-pathway model involving angiogenesis, nitric-oxide regulation and cell migration. The upstream molecular target remains uncertain, and most mechanistic evidence is preclinical.